Skip to main content
Clinical Trials/NCT02557230
NCT02557230RecruitingNot Applicable

Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience

Assiut University1 site in 1 country250 target enrollmentStarted: January 2016Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
250
Locations
1
Primary Endpoint
Event Free Survival (EFS)

Study Overview

Brief Summary

The aim of this study is to identify demographic & disease characteristics in pediatric oncology patients diagnosed with one of genitourinary tumors & treatment outcomes in these patients.

Detailed Description

Background:

Tumors of the kidney, bladder, prostate, testis, and adrenal represent a large part of the adult urologic practice, but are relatively infrequent in children.

Genitourinary tumors contribute to pediatric solid tumors. Wilms tumor, rhabdomyosarcoma, and germ cell tumors are the most common malignant genitourinary tumors in children.

The natural history and management of these tumors in the pediatric age is different from that of the adults. As result of the successful work of several clinical trial groups in recent decades, there has been a significant improvement in their cure rates.

Patients & Methods:

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Retrospective

Eligibility Criteria

Ages
— to 18 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients whose age less than or equal to 18 years.
  • Patients diagnosed with any of neoplasms affecting the genitourinary system.

Exclusion Criteria

  • Patients whose age more than 18 years.

Outcomes

Primary Outcomes

Event Free Survival (EFS)

Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years

Time from the date of initiation of treatment until disease progression, or death for any reason.

Overall survival (OS)

Time Frame: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years

Time from the date of initiation of treatment until death from any cause

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Ahmed Mohammed Morsy, MD

Lecturer, Pediatric Oncology Department

Assiut University

Study Sites (1)

Loading locations...

Similar Trials